Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H27N3O2.2ClH |
Molecular Weight | 402.358 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.O=C(N1CCN(CC1)C2CC2)C3=CC=C(CN4CCOCC4)C=C3
InChI
InChIKey=PBVFXCXXVLBYKF-UHFFFAOYSA-N
InChI=1S/C19H27N3O2.2ClH/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20;;/h1-4,18H,5-15H2;2*1H
Molecular Formula | C19H27N3O2 |
Molecular Weight | 329.4366 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22519922
Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methylphenidate hydrochloride 54 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:42:24 GMT 2025
by
admin
on
Mon Mar 31 19:42:24 GMT 2025
|
Record UNII |
1B5560RN9F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
929622-09-3
Created by
admin on Mon Mar 31 19:42:24 GMT 2025 , Edited by admin on Mon Mar 31 19:42:24 GMT 2025
|
PRIMARY | |||
|
300000042549
Created by
admin on Mon Mar 31 19:42:24 GMT 2025 , Edited by admin on Mon Mar 31 19:42:24 GMT 2025
|
PRIMARY | |||
|
1B5560RN9F
Created by
admin on Mon Mar 31 19:42:24 GMT 2025 , Edited by admin on Mon Mar 31 19:42:24 GMT 2025
|
PRIMARY | |||
|
66712477
Created by
admin on Mon Mar 31 19:42:24 GMT 2025 , Edited by admin on Mon Mar 31 19:42:24 GMT 2025
|
PRIMARY | |||
|
DTXSID00239212
Created by
admin on Mon Mar 31 19:42:24 GMT 2025 , Edited by admin on Mon Mar 31 19:42:24 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |